GSK P/E Ratio Analysis

The P/E ratio (price-to-earnings) measures how much investors pay for each $1 of a company's current earnings, so a 21.5x level means the stock costs 21.5 times its annual profit per share.

At 21.5x, GSK trades below the sector median of 22.9x, ranking in the 46th percentile among peers — meaning roughly 54% of sector companies carry higher valuations and 46% carry lower ones. Trend data is unavailable here, as only the current value of 21.5x was reported, leaving the year-over-year and quarter-over-quarter changes unspecified. The combination of a below-median valuation with no observable trend direction points to modest downside risk from multiple compression, but also lacks any upward momentum signal. This supports the overall NEUTRAL verdict directly: the stock is reasonably priced against its sector, offering neither a clear discount nor a premium worth acting

Frequently Asked Questions